PPARG and metabolic dysfunction-associated steatohepatitis: The AACE (American Association of Clinical Endocrinology) [41] and AASLD [10] clinical practice guidelines endorse the utilization of pioglitazone, a selective PPARγ (Peroxisome proliferator-activated receptor gamma) agonist, in cases of diagnosed MASH.